Downregulation of nuclear-encoded genes of oxidative metabolism in dialyzed chronic kidney disease patients. by Zaza, Gianluigi et al.
Downregulation of Nuclear-Encoded Genes of Oxidative
Metabolism in Dialyzed Chronic Kidney Disease Patients
Gianluigi Zaza1*., Simona Granata1., Valentina Masola1, Carlo Rugiu1, Francesco Fantin2,
Loreto Gesualdo3, Francesco Paolo Schena3, Antonio Lupo1
1 Renal Unit, Department of Medicine, University-Hospital of Verona, Verona, Italy, 2 Section of Geriatrics, Department of Medicine, University-Hospital of Verona, Verona,
Italy, 3 Renal, Dialysis and Transplant Unit, Department of Emergency and Transplantation, University of Bari, Bari, Italy
Abstract
Background: Mitochondria, essential eukaryotic cells organelles defined as the ‘‘powerhouse of the cell’’ because of their
ability to produce the vast majority of energy necessary for cellular metabolism, may have a primary role in the oxidative
stress-related intracellular machinery associated to chronic kidney disease (CKD).
Methods: To better assess this research assumption, we decided to study the key factors regulating mitochondrial oxidative
metabolism in CKD patients in peritoneal dialysis (PD, n = 15) using several bio-molecular methodologies.
Results: RT-PCR experiments demonstrate that the expression level of peroxisome proliferator-activated receptor gamma
coactivator 1 alpha (PGC-1a) and nuclear respiratory factor-1 (NRF-1), two genes primarily involved in mitochondrial
biogenesis and functions, were significantly hypo-expressed in peripheral blood mononuclear cells of PD patients compared
to healthy subjects (HS, n = 15). Additionally, mRNA levels of several PGC1-a downstream target genes (TFAM, COX6C,COX7C,
UQCRH and MCAD) were profoundly down-regulated in PD cells. TFAM protein analysis confirmed gene-expression results.
High plasmatic concentration of Malondialdehyde found in PD patients, confirmed the contribution of the oxidative stress
to these biological effects. Finally, Nuclear factor erythroid-derived 2-like 2 (NRF2 or NFE2L2), a transcription factor for
numerous antioxidant/detoxifying enzymes and one of its target genes, superoxide dismutase-2 mitochondrial (SOD2) were
up-regulated in PD compared to HS.
Conclusions: Our results revealed, for the first time, that CKD-PD patients’ PBMC, through a complex intracellular
biochemical machinery, are able to modulate their mitochondrial functions probably in the attempt to reduce oxidative
metabolic damage and to turn on a valuable defense cellular strategy against oxidative stress.
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Introduction
Chronic kidney disease (CKD) is a progressive and irreversible
deterioration of kidney function classified by the last international
guidelines into five stages according to glomerular filtration rate
[1]. In the last stage (end stage renal disease) the kidney
impairment is advanced and cellular/metabolic functions are
significantly altered and enable to guarantee normal body
homeostasis. Therefore, at this clinical phase, renal replacement
therapies (RRTs, peritoneal- or hemo-dialysis) or renal transplan-
tation are needed to ensure patient’s survival.
Although hemodialysis (HD) still represents the leading RRT, in
the last years, the number of patients undergoing peritoneal
dialysis (PD) procedure is increasing worldwide being a preferable
choice for young patients with high life expectancy and an elevated
probability to undergo renal transplantation. This is mainly related
to a lower activation of microinflammation, compared to HD [2],
better preservation of residual renal function [3] and higher
quality of life [4].
However, peritoneal catheter and dialysis solutions (character-
ized by high concentration of glucose, glucose degradation
products, low pH and high osmolality) used to remove waste
products generated from normal metabolic processes, uremic
toxins and to normalize body fluid and electrolytes [5] may still
determine the systemic activation of a complex intracellular
machinery leading to inflammation and oxidative stress [6–8].
In this context, the recruitment, rolling and activation of
peripheral blood mononuclear cells (PBMCs) may have a pivotal
etiopathogenic role.
As recently reported, transcriptomic analysis of PBMCs of PD
patients has shown high expression of important key regulators
of inflammation and oxidative stress (e.g. RELA, GSS) in this
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population [9] with mitochondria having a possible pivotal role
in the onset and development of these processes [10,11].
Mitochondria are essential eukaryotic cells organelles involved
in several metabolic pathways, including calcium signaling [12],
heme [13] and steroid synthesis [14], apoptosis [15]. This
intracellular elements are defined as the ‘‘powerhouse of the cell’’
because of their ability to produce the vast majority of energy
necessary for cellular metabolism through the oxidative phosphor-
ylation system (OXPHOS).
Structurally, they present an outer and inner membrane, the
latter of which would be impermeable to all molecules in the
absence of specific carriers and contains the OXPHOS complexes.
The respiratory flux is due to the donation of electrons from NAD-
or FAD-dependent substrates, via respiratory chain, to molecular
oxygen which is finally reduced to water. Simultaneously, the
energy conserving complexes I, III and IV build up a trans-
membrane electrochemical gradient by coupling the electron
transfer activity to proton translocation from the matrix to the
outer side of the inner mitochondrial membrane. Complex V
utilizes backward the electrochemical gradient for ATP synthesis.
During this process a small percentage of electrons may ‘‘leak’’
from the respiratory chain and partially reduce oxygen, forming
superoxide anion (O2
2) [16]. Consequently mitochondria are the
major source of ROS in the cell.
Recently increasing evidences showed mitochondrial dysfunc-
tion in a broad spectrum of renal disorders [17] and we previously
reported, for the first time, that CKD/HD patients exhibited an
impaired mitochondrial respiratory system.
Therefore, in order to improve our knowledge about the
mitochondria-related cellular changes occurring in the heteroge-
neous CKD population, to study possible intracellular defense
mechanisms against inflammation/oxidative stress and to identify
new diagnostic/prognostic biomarkers or therapeutic targets, we
decided to analyze in our in vivo study some of the key biological
cellular regulators of oxidative metabolism in uremic patients in
dialysis treatment.
We decided to focus on PD patients since the increasing interest
of the nephrological research on this large dialysis patients’
population and because, at present, no study has analyzed the
relationship between oxidative stress and mitochondrial deregula-
tion in this population.
Methods
Patients and Controls
A total of 30 subjects [n: 15 CKD in peritoneal dialysis (PD) and
n:15 healthy subjects (HS)], after signing informed consent, were
enrolled in our study. The main demographic and clinical features
are summarized in Table 1.
Thirteen PD patients have been treated with automated
peritoneal dialysis (APD) using a bicarbonate buffer (Physioneal,
Baxter) and 2 with a continuous ambulatory peritoneal dialysis
(CAPD) using a bicarbonate buffer (Physioneal, Baxter, Chicago,
IL, USA).
To avoid confounding factors, all patients suffering from
systemic autoimmune disorders, infectious diseases, diabetes,
chronic lung diseases, neoplasm, or inflammatory diseases and
patients receiving antibiotics, corticosteroids, or non-steroidal anti-
inflammatory agents were excluded. No patients had symptomatic
coronary artery diseases or a family history of premature
cardiovascular diseases.
Serum C-reactive protein (CRP) levels were measured in all
patients included in the study using high-sensitivity immunone-
phelometric (Dade Behring, Marbung, Germany) according to the
manufacturer’s protocol.
The study was carried out according to the Declaration of
Helsinki and approved by the Institutional Ethic Review Board of
the University Hospital ‘‘Policlinico di Bari’’, Bari, Italy (number
of registration: 599/CE).
Peripheral Blood Mononuclear Cells (PBMCs) Isolation
Fifteen ml whole blood were collected from all subjects included
in the study. For PD patients the biological material was obtained
during the outpatient clinical evaluations. PBMCs were isolated by
density separation over a Ficoll–PaqueTM (GE healthcare,
Sweden) gradient (460 g for 30 min) and washed three times with
PBS pH 7.4/1 mM EDTA (Sigma, Milan, Italy). Cells were
counted, and viability was assessed by trypan blue exclusion
method (.90% PBMCs were viable).
RNA Extraction and Real-Time PCR
Total RNA was isolated from PBMCs by RNeasy mini kit
Qiagen (QIAGEN AG, Basel, Switzerland). RNA was quantified
by Quant-iT RNA Assay kit with Qubit Fluorometer (Invitrogen).
Reverse transcription of RNA was performed using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosystems),
following the manufacturer’s instructions. One mg of RNA was
reverse transcribed using random primer and MultiScribe Reverse
Transcriptase. Real-time PCR amplification reactions were
performed in duplicate in 20 ml of final volume via SYBR Green
chemistry on ABI-Prism 7700 (Applied Biosystem). PCR protocol
was performed using QuantiTect Primer Assays (Qiagen, Basel,
Switzerland) for PGC-1a, NRF-1, TFAM, MCAD, NRF2, SOD2
and b-actin: 50uC for 2 min, 95uC for 2 min and 40 two-step
cycles: 95uC for 15 sec and 60uC for 30 sec. For COX6C,
COX7C (subunits of complex IV or Cytochrome c oxidase) and
UQCRH (subunit of Complex III or ubiquinol-cytochrome c
reductase) the primers were designed by the aid of the Primer3
software (frodo.wi.mit.edu). The forward and reverse primer
sequences were: COX6C forward 59-CTTTGTA-
Table 1. Demographics and clinical characteristics of study
group.
HS PD p.value
Number 15 15 n.s.
Gender (M/F) 8/7 9/6 n.s.
Age (years) 49.965.7 51.962.5 n.s.
Cause of CKD (GN, ADPKD,
RVD, ESRD, unknown)
/ 6,1,4,1,2 /
Time on dialysis (years) / 2.762.1 /
BMI (Kg/m2) 2565.0 26.1963.4 n.s.
Systolic blood pressure (mmHg) 120.562.7 134.767.6 ,0.001
Diastolic blood pressure (mmHg) 74.265.3 8069.7 n.s.
Total protein (g/dl) 7.0860.3 6.8460.5 n.s.
Albumin (g/dl) 3.961.2 3.3460.6 n.s.
Hemoglobin (g/dl) 13.561.3 12.2760.9 ,0.01
Hs-CRP (ng/ml) 0.6960.7 12.5168.5 ,0.001
Values are expressed as mean 6 SD. GN, glomerulonephritis; ADPKD, adult
dominant polycystic disease; RVD, renal vascular disease; ESRD, end-stage renal
disease. BMI, body mass index; Hs-CRP, high sensitivity- C reactive protein. p-
values determined by t-test and Chi-squared test.
doi:10.1371/journal.pone.0077847.t001
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TAAGTTTCGTGTGG-39 and reverse 59-ATTCATGTGTCA-
TAGTTCAGG-39; COX7C forward 59-CCCTGGGAA-
GAATTTGCCA-39 and reverse 59-GGAACTGAAACATCCT-
TATG-39; UQCRH forward 59-AGGGACCATTGCGTGGCC-
39 and reverse 59-AGCTACCAGCCTAAGCCAAA-39.
Universal master mix obtained from Kapa Biosystems included
all reagents. The b-actin gene amplification was used as a
reference standard to normalize the target signal. Amplification
specificity was controlled by a melting curve analysis and the
amount of mRNA target was evaluated using the comparative Ct
method.
Western Blot Analysis for TFAM
Isolated PBMCs from 10 PD patients and 8 HS were lysed in
RIPA buffer (1 mM phenylmethylsulphonylfluoride, 5 mM
EDTA, 1 mM sodium orthovanadate, 150 mM sodium chloride,
8 mg/ml leupeptin, 1.5% NonidetP-40, 20 mM Tris–HCl,
pH 7.4). The lysates were kept on ice for 30 min and centrifuged
Figure 1. Peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1-a) and nuclear respiratory factor-1 (NRF-1)
gene expression by Real-Time PCR in PBMCs from healthy subjects (HS) and chronic kidney disease patients in peritoneal dialysis
(PD). The histograms represent the mean6 SD of PGC1-a (A) and NRF-1 (B) expression level, determined by Real-Time PCR in PBMCs from 15 HS and
15 PD patients. For both genes the expression level was significantly lower in PD compared to HS (**p,0.001).
doi:10.1371/journal.pone.0077847.g001
Figure 2. Transcription factor A, mitochondrial (TFAM) gene and protein expression in PBMCs from healthy subjects (HS) and
chronic kidney disease patients in peritoneal dialysis (PD). (A) The histogram represents the mean 6 SD of TFAM expression level,
determined by Real-Time PCR in PBMCs from 15 HS and 15 PD patients. (B) Dot-plot represents the normalized TFAM protein level in total cell lysates
of 8 HS and 11 PD patients assessed by Western blotting and (C) the representative western blotting experiment for TFAM. The line represents the
mean value. Both TFAM mRNA and protein level was significantly lower in PD patients compared to HS.
doi:10.1371/journal.pone.0077847.g002
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at 10,000 g at 4uC for 10 min. The supernatants were collected
and stored at 280uC until used. Aliquots containing 30 mg of
proteins from each lysate were subjected to SDS–PAGE on a
CriterionTM TGX Any kD Stain-FreeTM (Biorad) and then electro-
transferred onto PVDF membrane (Biorad) by Trans-Blot Turbo
transfer system (Biorad). The filter was blocked with 5% milk
powder in TBS containing 0.1% Tween-20 (TBS-T). Membranes
were probed with primary antibody against TFAM (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and incubated with
secondary antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Horseradish peroxidase was detected with the ECL-
enhanced chemiluminescence system (Amersham, Buckingham-
shire, UK). The same membranes were stripped and proteins were
rehybridized with anti-b-actin antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA). Images were acquired using a
scanner EPSON Perfection 2580 Photo (EPSON, Long Beach,
CA, USA) and quantified by Image J 1.34 Software (http://rsb.
info.nih.gov/ij/). The intensity of bands, corresponding to the
TFAM protein, was normalized to the b-actin signal.
Figure 3. Medium chain acyl CoA dehydrogenase (MCAD) gene
expression in PBMCs from healthy subjects (HS) and chronic
kidney disease patients in peritoneal dialysis (PD). The
histogram represents the mean 6 SD of MCAD expression level,
determined by Real-Time PCR in PBMCs from 15 HS and 15 PD patients.
The expression level was significantly lower in PD compared to HS
(**p,0.001).
doi:10.1371/journal.pone.0077847.g003
Figure 4. COX6C, COCX7C and UQCRH gene expression by Real-Time PCR in PBMCs from healthy subjects (HS) and chronic kidney
disease patients in peritoneal dialysis (PD). The histograms represent the mean 6 SD of COX6C (A) COX7C (B) and UQCRH (C) expression level,
determined by Real-Time PCR in PBMCs from 15 HS and 15 PD patients. For all these genes the expression level was significantly lower in PD
compared to HS (**p,0.001).
doi:10.1371/journal.pone.0077847.g004
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Western Blot Analysis for Nuclear Protein Expression of
NRF2
Nuclear extracts of freshly isolated PBMCs from 5 randomly
selected HS and 5 PD patients were obtained according to the
published protocol by Almeida et al [18]. PBMCs were washed
with ice-cold PBS and resuspended in buffer A (10 mM HEPES,
10 mM NaCl, 3 mM MgCl2, 1 mM EGTA, 0.1% Triton X-100,
pH 7.5), supplemented with 50 mM NaF, 1 mM Na3VO4, 1 mM
DTT, 1 mM PMSF, and complete protease inhibitor cocktail
(Roche) on ice for 40 min, then centrifuged at 2,400 g for 10 min.
The pellets containing nuclei were resuspended in buffer B
(25 mM HEPES, 300 mM NaCl, 5 mM MgCl2, 1 mM EGTA,
20% glycerol, pH 7.4), supplemented with 50 mM NaF, 1 mM
Na3VO4, 1 mM DTT, 1 mM PMSF, and complete protease
inhibitor cocktail on ice for 60 min. The lysates were centrifuged
at 12,000 g for 20 min, the supernatants were collected, and the
amount of nuclear protein was measured using the Bio-Rad
protein assay reagent.
Subsequently, nuclear extracts (20 mg) were resolved in 9%
SDS-PAGE and electrotransferred onto nitrocellulose membranes.
The filter was blocked with 5% milk powder in TBS-T.
Membranes were probed with anti-NRF2 (Genetex
GTX103300; 1:500) and anti-Lamin B (sc-2616, Santa Cruz
Biotechnolgy 1:1000) antibodies. After three washes in TBST, the
membranes were incubated with the secondary peroxidase
conjugated antibodies. The signal was detected by ECL-enhanced
chemiluminescence system (Amersham, Buckinghamshire, UK)
according to the manufacturer’s instructions. Images were
acquired using a scanner EPSON Perfection 2580 Photo (EPSON,
Long Beach, CA, USA) and quantified by Image J 1.34 Software
(http://rsb.info.nih.gov/ij/). The intensity of bands, correspond-
ing to the NRF2 protein, was normalized to the Lamin B signal.
Thiobarbituric Acid Reactive Substances (TBARS) Assay
Plasmatic measurement of Malondialdehyde (MDA) as TBARS
was performed for all subjects included in the study using a
commercially available kit (AbNOVA Abnova, Walnut, CA)
according to the manufacturer’s instructions.
Resting Metabolic Rate
Resting metabolic rate (RMR) was assessed by indirect
calorimetry with the use of an MMC Horizon System 6 (Beckman
Sensormedics, Milan, Italy) that measures resting oxygen uptake
and resting carbon dioxide production. The subjects were
familiarized with the canopy of the calorimeter so that they did
not feel suffocated during the measurement period. They were
instructed to avoid hyperventilating, fidgeting, and falling asleep.
Gas was measured in the morning in the supine position after the
subjects had fasted 12 h. Values were considered reliable after a
20-min nonstop period when differences in consecutive values
were ,5%; at this point, gas measurements were continued for
another 20 min, and mean values for resting oxygen uptake and
resting carbon dioxide production were calculated. The CV for
duplicate measurements in 12 subjects was 5%.
Statistical Analysis
Results were expressed as mean 6 SD. Student’s t-test and Chi-
squared test were used to assess differences in clinical, demo-
graphic and experimental features. A value of p,0.05 was
considered to be statistically significant. R 2.0.1 statistical software
was used to perform the above analyses (www.r-project.org).
Results
Peroxisome Proliferator-activated Receptor Gamma
coactivator 1 Alpha (PGC1-a) and Nuclear Respiratory
Factor 1 (NRF-1) Gene Expression
To assess whether PBMCs isolated from CKD patients
undergoing PD treatment showed an alteration of the cellular
machinery associated to the oxidative energy metabolism, we
measured by RT-PCR the expression level of peroxisome
proliferator-activated receptor gamma coactivator 1 alpha
(PGC1-a) and Nuclear respiratory factor 1 (NRF-1), two genes
encoding, respectively, for a transcriptional coactivator and a
transcription factor that together stimulate the expression of a
Figure 5. Malondialdehyde (MDA) levels in plasma of healthy
subjects (HS) and chronic kidney disease patients in peritoneal
dialysis (PD). Dot-plot represents plasma MDA levels in 15 HS and 15
PD patients. Malondialdehyde (MDA) was measured as TBARS. The line
represents the mean value. MDA level was higher in PD compared to
HS.
doi:10.1371/journal.pone.0077847.g005
Figure 6. Resting metabolic rate (RMR) assessment in healthy
subjects (HS) and chronic kidney disease patients in peritoneal
dialysis (PD). Dot-plot represents the RMR assessed by indirect
calorimetry in 15 HS and 15 PD patients. RMR levels were similar in the
two study groups.
doi:10.1371/journal.pone.0077847.g006
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broad set of nuclear genes involved in mitochondrial biogenesis
and functions.
As reported in figure 1, both genes resulted significantly down-
regulated in PD compared to HS.
Mitochondrial Transcription Factor A (TFAM) Gene and
Protein Levels
Since TFAM is the major gene regulated by NRF-1 and it
regulates mitochondrial transcription and replication, we decided
to measure its gene expression in all subjects included in the study.
As expected, PD patients showed a significant TFAM mRNA
down-regulation compared to HS (Figure 2A). Protein analysis by
western blot confirmed the results obtained by gene expression
(Figure 2B).
Medium Chain Acyl CoA Dehydrogenase (MCAD) Gene
Expression
To confirm the reduced PGC1-a activity we evaluated the
mRNA level of MCAD, an oxidoreductase enzyme tightly
regulated by this coactivator, that catalyzes the first step of
mitochondrial fatty acid beta-oxidation, in our PD patients and
HS. MCAD gene expression was significantly lower in PD
compared to HS (Figure 3).
Oxidative Phosphorylation System (OXPHOS) Subunits
Mitochondrial oxidative phosphorylation system (OXPHOS)
plays a central role for energy homeostasis in mammals. This
machinery is finely regulated by several factors including PGC-1a
and NRF-1. Therefore, we decided to analyze whether the down
regulation of these factors in our CKD-PD patients induced down-
regulation of expression of genes encoding for mitochondrial
OXPHOS subunits. Our results revealed that the expression level
of genes encoding for UQCRH (complex III subunit) and
COX6C/COX7C (complex IV subunits) were significantly
hypo-expressed in our PD patients compared to HS (Figure 4).
These results suggest a possible reduction of OXPHOS activity.
Oxidative Stress Evaluation by Thiobarbituric Acid
Reactive Substances (TBARS)
To assess the relationship between PCG1-a, NRF-1 deregula-
tion and oxidative stress, we measured the TBARS levels, products
of oxidative damage to lipid, in all subjects included in our study.
In particular, we analyzed the plasmatic levels of malondialdehyde
(MDA), one of several low-molecular-weight end products formed
via the decomposition of certain primary and secondary lipid
peroxidation products. MDA levels were significantly higher in our
PD patients compared to HS (Figure 5) demonstrating an high
oxidative stress in our dialysis patients.
Figure 7. NRF-2 and SOD2 gene expression by Real-Time PCR in PBMCs from healthy subjects (HS) and chronic kidney disease
patients in peritoneal dialysis (PD). The histograms represent the mean 6 SD of NRF-2 (A) and SOD2 (B) expression level, determined by Real-
Time PCR in PBMCs from 15 HS, 15 PD patients. For both genes the expression level was significantly higher in PD compared to HS (*p,0.01).
doi:10.1371/journal.pone.0077847.g007
Figure 8. Nuclear factor erythroid-derived 2-like 2 (NRF2)
protein expression in nuclear extracts of PBMCs from healthy
subjects (HS) and chronic kidney disease patients in peritoneal
dialysis (PD). (A) Dot-plot represents the normalized NRF2 protein
level in nuclear extracts of 5 HS and 5 PD patients assessed by Western
blotting and (B) the representative western blotting experiment for
NRF2. The line represents the mean value. NRF2 protein level was
significantly higher in PD patients compared to HS.
doi:10.1371/journal.pone.0077847.g008
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Nutritional Status Evaluation Using the Resting Metabolic
Rate (RMR)
To exclude a possible influence of the nutritional status on the
previous results, we performed an indirect calorimetry test to
measure the resting metabolic rate (RMR) on all the study
population. Concordantly with other reports [19], we did not find
any differences between PD and HS (Figure 6).
Evaluation of the Antioxidant Cellular Response by NRF2
and SOD2 Gene Expression Analysis
Finally, to better define the antioxidant response against the
cytotoxic effects of oxidative stress, we evaluated the expression
level of Nuclear factor-erythroid-2-related factor 2 (NRF2 or
NFE2L2) and Superoxide dismutase 2, mitochondrial (SOD2) in
our CKD-PD patients and HS.
As predictable, both genes were up-regulated in PD compared
to HS demonstrating an enhanced activation of the cellular
antioxidant machinery in this study group (Figure 7).
NRF2 Protein Levels
Because of NRF2 mediates the transcriptional response of cells
to oxidative stress by the translocation into nucleus, we evaluated
its protein level in nuclear extracts from PBMCs of HS and CKD-
PD patients. Concordantly to gene expression analysis, NRF2
protein level resulted significantly higher in CKD-PD patients
compared to HS (Figure 8).
Discussion
Oxidative stress and mitochondrial activity are key elements of
many pathological conditions, including neurodegenerative disor-
ders, diabetes, cardiovascular disease and cancer [20–23].
Moreover, our research group has recently demonstrated, for
the first time, a close link between mitochondrial deregulation and
oxidative stress in chronic kidney disease (CKD) patients in
conservative and hemodialysis (HD) treatment [24]. In particular,
using an innovative high-throughput technology, we discovered
that several biological elements involved in the oxidative
phosphorylation system and two key constituents of the mito-
chondrial complex IV (COXI and COXIV) were deregulated in
CKD/HD patients compared to healthy controls. In addition,
complex IV activity, the terminal enzyme of the mitochondrial
respiratory chain catalyzing the electron transfer from reduced
cytochrome c to oxygen [25], resulted significantly lower in CKD/
HD patients compared to healthy subjects demonstrating a
reduced activity of oxidative phosphorylation system in this
population. However, at the state of art, the complete cellular
mechanism involved in this intricate biological system is still
completely unknown.
Therefore, to better comprehend the mitochondria-related
biochemical/metabolic cellular alterations in CKD, we decided
to use a well standardized biomolecular methodologies (e.g., RT-
PCR, western-blotting) to measure the expression level of some
key biological cellular regulators of the oxidative metabolism in
patients with elevated kidney damage undergoing peritoneal
dialysis (PD) treatment.
Figure 9. Supposed mechanism of PGC1-a/NRF1-NRF2 pathway anti-oxidative stress cellular defense in chronic kidney disease
patients in peritoneal dialysis treatment. Oxidative stress alters the interaction of Kelch-like ECH-associated protein 1 (Keap1) and Nuclear factor
erythroid-derived 2-like 2 (Nrf2), thereby liberating Nrf2 activity from repression by Keap1. NRF2 migrates into the nucleus were it activates the
transcription of Superoxide dismutase 2, mitochondrial (SOD2). At the same time, oxidative stress causes the down-regulation of Peroxisome
proliferator-activated receptor gamma coactivator 1 alpha (PGC1-a) and Nuclear respiratory factor-1 (NRF-1) with the consequent down-regulation of
PGC-1a downstream target genes (TFAM, COX6C, COX7C, UQCRH and MCAD). The reduced TFAM expression causes a decrease in mitochondrial
transcription and replication. The down-regulation of all these factors suggests the decrease in mitochondrial OXPHOS activity in order to reduce ROS
accumulation and creating an antioxidant feedback.
doi:10.1371/journal.pone.0077847.g009
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PD is a renal replacement therapy that, instead of hemodialysis,
is associated with better preservation of residual renal function,
initial survival advantage, reduced erythropoiesis stimulatory agent
requirements and preservation of vascular access sites [26–28].
However, the use of ‘‘unphysiologic’’ conventional PD fluids
(characterized by acidic pH, high lactate concentrations, high
osmolality, high glucose concentrations, and contamination by
glucose degradation products) may contribute to the onset/
development of several adverse outcomes [29–32] and to the
activation of oxidative stress [7]. Although well described, the
molecular mechanisms associated to latter condition are still not
completely known.
To better address this point, we focused on the Peroxisome
proliferator-activated receptor gamma coactivator 1 alpha (PGC-
1a)-related intracellular machinery. PGC-1a is a well known
master regulator of mitochondrial oxidative metabolism [33]. Its
expression seems finely tuned to reflect cellular energy needs, with
conditions of increased energy demands inducing its expression
[34,35]. PGC-1a performs this task by coactivating a large
number of transcription factors, including, among others, nuclear
respiratory transcription factor 1 (NRF-1) and in this way, it
regulates the activity of numerous nuclear genes encoding
mitochondrial proteins [36].
Interestingly, our RT-PCR experiments demonstrated that the
expression levels of PGC-1a, NRF-1 and the other analyzed
downstream target genes were significantly down-regulated in PD
patients compared to HS. Therefore PBMCs of CKD patients
showed a specific down-regulation of several nuclear-encoded
genes involved in the mitochondrial biogenesis and functions
(TFAM, COX6C, COX7C, UQCRH and MCAD).
TFAM has a key biological role because, after migration into
mitochondria, it regulates mitochondrial DNA transcription and
replication [37]. COX6C and COX7C encode for two subunits of
the cytochrome c oxidase (COX or Complex IV), UQCRH is a
component of the ubiquinol-cytochrome c reductase complex
(complex III), which catalyzes electron transfer from succinate and
nicotinamide adenine dinucleotide-linked dehydrogenases to
cytochrome c [38]. MCAD, then, is an oxidoreductase enzyme
regulated by PGC1-a, that catalyzes the first step of mitochondrial
fatty acid beta-oxidation [39].
Based on previous literature evidences reporting that reactive
oxygen species may induce PGC-1a down-regulation [40], we
assumed that this biological/biochemical complex, through a
mitigation of the mitochondrial OXPHOS activity, could repre-
sent a protective adaptive response against chronic cellular
perturbation associated to the kidney disease-related oxidative
injury.
Our CKD patients, in fact, showed higher plasma concentration
of Malondialdehyde (MDA), a thiobarbituric acid reactive
substance (TBARS) commonly known as a marker of oxidative
stress [41], compared to healthy controls.
Additionally, our results confirmed previous literature evidences
reporting that advanced CKD ‘‘per se’’ mainly through the
accumulation of several circulating uremic toxins (e.g., indoxyl
sulfate, p-cresyl sulfate) [42,43] and the interaction of PBMCs with
bio-incompatible dialysis devices can cause their activation with
imbalance between pro- and anti-oxidant activities resulting in
high oxidative stress [8,44].
This hypothesis was also in part confirmed by our finding of an
additional activated cellular anti-oxidant machinery in PBMCs of
PD patients. Specifically, Nuclear factor erythroid-derived 2-like 2
(NRF2 or NFE2L2), a transcription factor regulating the
expression of numerous antioxidant/detoxifying enzymes, and
one of its down-stream target genes superoxide dismutase-2
mitochondrial (SOD2) [45] resulted significantly up-regulated in
our CKD-PD population. SOD2 binds to the superoxide
byproducts of oxidative phosphorylation and converts them to
hydrogen peroxide and diatomic oxygen [46].
Therefore, all together, our results, although generated on a
small but well selected patients’ population, revealed, for the first
time, a fine regulated intracellular biochemical system associated
to oxidative stress response in CKD patients. It is plausible that
this redox-dependent mechanism could have a pivotal role in
antioxidant defense cellular strategy occurring in cells of these
patients (Figure 9). However, further studies are necessary to better
delineate all the biological/biochemical mechanisms involved.
The main limitation of our study is the lack of the analysis of all
potential clinical variables able to influence the ‘‘mitochondrial’’
transcriptomic profile primarily due to the time and cost
consuming of a global analytic/research strategy.
Moreover, our in vitro model failed to corroborate our in vivo
findings (See File S1 and Figure S1, 2, 3 and 4). In fact, PBMCs
stimulated with high glucose PD dialysis solutions showed the up-
regulation of all the previous analyzed genes. These contradictory
results clearly demonstrated the unquestionable complexity of this
machinery in which all together uremia, microinflammation,
subclinical/clinical peritoneal infections, acidosis, electrolytic
unbalance contribute to the onset and development of this
biological/clinical condition. Therefore, we strong encourage a
collaborative international research program to address these
points.
Finally, we can not exclude that, in future, the modulation of
this machinery could turn on as a valuable point of therapeutic
intervention to reduce oxidative stress-related clinical complica-
tions in CKD patients in both conservative and dialysis treatment.
Supporting Information
Figure S1 Peroxisome proliferator-activated receptor
gamma coactivator 1 alpha (PGC1-a), nuclear respira-
tory factor-1 (NRF-1) and Transcription factor A,
mitochondrial (TFAM) gene expression in PBMC from
3 healthy subjects stimulated with PD fluid. The
histograms represent the mean 6 SD of PGC1-a (A), NRF-1 (B)
and TFAM (C) level of expression, determined by Real-Time PCR
in PBMC from 3 HS stimulated with PD fluid. All the three genes
resulted significantly up-regulated after 6 and 24 h of incubation
with PD fluid (#p,0.05; ##p,0.01 versus CTR).
(TIF)
Figure S2 Medium chain acyl CoA dehydrogenase
(MCAD) gene expression in PBMC from 3 healthy
subjects stimulated with PD fluid. The histogram represents
the mean 6 SD of MCAD level of expression, determined by
Real-Time PCR in PBMC from 3 HS stimulated with PD fluid.
The expression level was significantly up-regulated after 6 and
24 h of incubation with PD fluid (#p,0.05 versus CTR).
(TIF)
Figure S3 COX6C, COCX7C and UQCRH gene expres-
sion in PBMC from 3 healthy subjects stimulated with
PD fluid. The histograms represent the mean 6 SD of COX6C
(A) COX7C (B) and UQCRH (C) level of expression, determined
by Real-Time PCR in PBMC from 3 HS stimulated with PD fluid.
All the three genes resulted significantly up-regulated after 6 and
24 h of incubation with PD fluid (#p,0.05; ##p,0.01 versus
CTR).
(TIF)
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Figure S4 NRF-2 and SOD2 gene expression by Real-
Time PCR in PBMC from 3 healthy subjects stimulated
with PD fluid. The histograms represent the mean 6 SD of
NRF-2 (A) and SOD2 (B) level of expression, determined by Real-
Time PCR in PBMC from 3 HS stimulated with PD fluid. Both
genes were up-regulated after 6 and 24 h of incubation with PD
fluid (#p,0.05; ##p,0.01 versus CTR).
(TIF)
File S1 Supplementary methods.
(DOC)
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